These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 21400918

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

  • 3. [Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration].
    Tano Y, Pegaptanib Sodium Multi-center Study Group.
    Nippon Ganka Gakkai Zasshi; 2008 Jul; 112(7):590-600. PubMed ID: 18702350
    [Abstract] [Full Text] [Related]

  • 4. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Schiller DS.
    Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pegaptanib for neovascular age-related macular degeneration.
    Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.
    N Engl J Med; 2004 Dec 30; 351(27):2805-16. PubMed ID: 15625332
    [Abstract] [Full Text] [Related]

  • 7. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupCentre for Vision Sciences, The Queen's University of Belfast and The Royal Victoria Hospital, Belfast, United Kingdom., Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M.
    Ophthalmology; 2006 Sep 30; 113(9):1508.e1-25. PubMed ID: 16828500
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pegaptanib for neovascular age-related macular degeneration.
    Maberley D.
    Issues Emerg Health Technol; 2005 Dec 30; (76):1-4. PubMed ID: 16544440
    [Abstract] [Full Text] [Related]

  • 11. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Abrams P.
    Clin Ther; 2007 Sep 30; 29(9):1850-61. PubMed ID: 18035187
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience.
    Sivaprasad S, Hykin P, Saeed A, Beatty S, Grisanti S, Staurenghi G, Olea JL, Campos A, Barbosa A, Rito L, Silva R, Faria R, Eldem B, Kadayifçilar S, Kolar P, Feucht N, Maestroni L.
    Eye (Lond); 2010 May 30; 24(5):793-8. PubMed ID: 19786957
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. RPE tears after pegaptanib treatment in age-related macular degeneration.
    Chang LK, Flaxel CJ, Lauer AK, Sarraf D.
    Retina; 2007 Sep 30; 27(7):857-63. PubMed ID: 17891009
    [Abstract] [Full Text] [Related]

  • 17. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
    Doggrell SA.
    Expert Opin Pharmacother; 2005 Jul 30; 6(8):1421-3. PubMed ID: 16013991
    [Abstract] [Full Text] [Related]

  • 18. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
    Williams AJ, Fekrat S.
    Am J Ophthalmol; 2006 Oct 30; 142(4):683-4. PubMed ID: 17011868
    [Abstract] [Full Text] [Related]

  • 19. [Pegaptanib sodium in treatment of choroidal neovascularization secondary to age-related macular degeneration. One year results].
    Wykrota H, Gajdzik-Gajdecka U, Trzciakowski K, Smuzyńska M.
    Klin Oczna; 2007 Oct 30; 109(10-12):394-401. PubMed ID: 18488381
    [Abstract] [Full Text] [Related]

  • 20. Compassionate use of intravitreal pegaptanib in patients with age-related macular degeneration.
    Ricci F, Missiroli F, Cedrone C, Grossi M, Regine F.
    Semin Ophthalmol; 2010 Oct 30; 25(1-2):16-20. PubMed ID: 20507192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.